Patients with pulmonary arterial hypertension (PAH) who were treated with treprostinil using an implantable infusion pump experienced few serious complications.
A combinatorial model was devised to predict pulmonary hypertension using systolic pulmonary artery pressure and forced vital capacity in older adults.
Elevated pulmonary artery systolic pressure was found to be associated with a worse prognosis in patients with heart failure with severe secondary mitral regurgitation.
Researchers sought to determine if selexipag can be associated with lower hospitalization rates through analysis of real-world hospitalization rates of patients taking either selexipag or treprostinil.
Physicians frequently underestimate or overestimate disease progression risk in patients with World Health Organization functional class II pulmonary arterial hypertension.
The purpose of this study was to determine whether baseline pulmonary hypertension influences the outcome of transcatheter mitral valve repair (TMVr) in patients presenting with HF with SMR.